LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
Podcasts & Webcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
BioCentury-BayHelix China Healthcare Summit
East-West Healthcare Reception
BioCentury-BayHelix East-West Summit
Bio€quity Europe
BioCentury Grand Rounds Inquiry
Grand Rounds U.S.
Grand Rounds Europe
The BioCentury Show
Webinars - Upcoming & On-Demand
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Jul 26, 2024
Finance
Public Equity Report: Palvella lands on NASDAQ via Pieris merger
Plus: Verastem’s follow-on and Hangzhou Jiuyuan’s IPO plans
Read More
BioCentury
|
May 31, 2024
Finance
Public Equity Report: Insmed, Merus raise combined $1B+ after readouts
Plus: PIPEs help Celcuity, Cargo advance clinical programs
Read More
BioCentury
|
Jan 12, 2023
Deals
Jan. 12 Quick Takes: Cambrian launches Isterian to advance fibrosis programs
Plus: Oramed’s oral insulin misses in diabetes and Tricida going bankrupt
Read More
BioCentury
|
Nov 8, 2022
Distillery Therapeutics
Lymophatic-absorbed multi-kinase inhibitor for myelofibrosis
Read More
BioCentury
|
Feb 17, 2022
Deals
Cambrian launches new subsidiary to develop mTOR inhibitors
Novartis deal gives Tornado Therapeutics assets for age-related diseases
Read More
BioCentury
|
Jan 21, 2022
Discovery & Translation
ToolGen’s gene editor for hemophilia A and B; plus Praxis, TellBio and more
BioCentury’s roundup of translational news
Read More
BioCentury
|
Dec 3, 2021
Distillery Therapeutics
MAPK6 inhibition to sensitize cancers to mTOR inhibitors
Read More
BioCentury
|
Nov 24, 2021
Product Development
Nov. 23 Quick Takes: Aadi’s Fyarro approved for rare sarcoma
Plus BMS’s Zeposia, LoQus23’s seed round, Simcere’s COVID antiviral and more
Read More
BioCentury
|
Oct 8, 2021
Product Development
Diadem’s prognostic Alzheimer’s blood test bets on p53 biology
The Italian company plans to launch its test as a screening tool late this year
Read More
BioCentury
|
Jul 22, 2021
Deals
Eyeing ‘backbone’ in breast cancer, Pfizer pays $1B for Arvinas’ protein degrader
Milestones
Read More
Items per page:
10
1 - 10 of 420
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help